Skip to main content

NEONC TECHNOLOGIES HOLDINGS, INC.

Filed Feb 6, 2026.

View on SEC.gov

About this filing

A company's registration of shares for sale to the public, often for a first offering. It describes the business, its risks and how the company plans to use the money.

period unavailable · Filed Feb 6, 2026

NTHI$3.49+9.1%Stored close · as of Nov 6, 2026
See the whole filing, with its images and exhibits
Contents

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This prospectus contains forward-looking statements that can involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this prospectus, including statements regarding our future results of operations and financial position, business strategy, prospective products, product approvals, research and development costs, future revenue, timing and likelihood of success, plans and objectives of management for future operations, future results of anticipated products and prospects, plans and objectives of management are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.

●the timing, progress and results of preclinical studies and clinical trials for our current and future product candidates, including statements regarding the timing of initiation and completion of studies or trials and related preparatory work, the period during which the results of the trials will become available and our research and development programs;
●the timing, scope or likelihood of regulatory submissions, filings, and approvals, including final regulatory approval of our product candidates;
●our ability to develop and advance product candidates into, and successfully complete, clinical trials;
●our expectations regarding the size of the patient populations for our product candidates, if approved for commercial use;
●the implementation of our business model and our strategic plans for our business, product candidates and technology;
●the rate and degree of market acceptance and clinical utility of our product candidates, in particular, and cell therapy, in general;
●our competitive position;
●the scope of protection we and/or our licensors are able to establish and maintain for intellectual property rights covering our product candidates;
●the impact of laws and regulations.
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.